Ardit Feinaj

This study aimed to evaluate the potential of plasma-based proton magnetic resonance spectroscopy (1H-MRS) for non-invasive discrimination between clear cell renal cell carcinoma (ccRCC), benign renal masses (angiomyolipoma and oncocytoma) and healthy controls by identifying disease-specific metabolic signatures.

Introduction Hypercoagulability is a well-recognized hallmark of malignancy and remains one of the most clinically significant complications among patients with active cancer. The interplay of tumor-derived procoagulant activity, cytokine-mediated inflammation, and endothelial dysfunction contributes to a prothrombotic environment that predisposes to both venous and arterial thromboses, including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke (1).